|Bid||0.00 x 3200|
|Ask||0.00 x 1000|
|Day's Range||6.98 - 8.05|
|52 Week Range||6.04 - 25.10|
|Beta (3Y Monthly)||4.07|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
A wave of disappointing earnings caused a bloodbath in marijuana ETFs last week. However, talks of an end to the federal embargo on marijuana could turn this segment around.
Top cannabis players have lost 75% in market value over the last year. Here's why investors can expect weakness to continue in the short-term.
Investing.com – Canopy Growth has plunged in recent months to levels that finally make it worth buying, Bank of America said on Wednesday, sending shares of the Canadian cannabis producer sharply higher.
Marijuana stock Cronos Group (TSX:CRON)(NASDAQ:CRON) is undergoing massive transformation. You need to know these coming changes.
TORONTO — Cannabis company Cronos Group Inc. reported a profit in its third quarter, boosted by an $835-million gain in derivative liabilities, as revenue grew to $12.7 million.The company says its net profit amounted to $788 million or 53 cents per diluted share for the quarter ended Sept. 30. That compared with a loss of $7.3 million or four cents per share in the same quarter last year.Cronos says its adjusted earnings before interest, taxes, depreciation and amoritization amounted to a loss of $23.9 million in its most recent quarter compared with a loss of $3.2 million a year ago.Revenue was up from $3.8 million in the same quarter last year and up from $10.2 million in the second quarter of 2019.Analysts had expected Cronos to report $14.1 million in revenue for its third quarter, according to financial markets data firm Refinitiv.Cronos says it sold 3,142 kilograms of cannabis in Canada in the quarter, up from 514 kilograms in the third quarter last year and 1,584 kilograms in the second quarter of 2019.This report by The Canadian Press was first published Nov. 12, 2019.Companies in this story: (TSX:CRON) The Canadian Press
Here’s what you need to know about Cronos Group’s (TSX:CRON)(NASDAQ:CRON) latest quarterly financial results.
All eyes will be on President Trump Tuesday for U.S.-China trade war updates. Walmart, Nvidia, and others are set to report their quarterly earnings. And why Casey's General Stores (CASY) is a Zacks Rank 1 (Strong Buy) right now...
Cronos (CRON) delivered earnings and revenue surprises of 33.33% and -3.05%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
Closed Redwood U.S. Hemp-Based Products Platform and Cronos Fermentation Facility Acquisitions Announced the launch PEACE+™, A New Hemp-Derived U.S. Brand Advanced Operational.
The latest U.S.-China trade war news that could see the world's two largest economies roll back tariffs. Q3 earnings results from the likes of Qualcomm and Square. And why Yeti is a Zacks Rank 1 (Strong Buy) stock...
After parting ways with Canadian cannabis giant Canopy Growth, Bruce Linton is joining the board of U.S. multi-state operator Vireo Health.
Should investors think about buying some shares of Cronos (CRON) ahead of earnings, as a bet on a marijuana market comeback?
Aphria’s stock price has risen 8.9% since reporting its Q1 earnings on October 15. The cannabis sector's weakness offset some of these gains.
Cannabis company Cronos Group has expanded its presence in the US cannabidiol market through a tie-up with tobacco company Altria Group.
Canopy Growth (CGC) (WEED) and Cronos Group (CRON) are set to release their earnings next week. The cannabis sector has been on a roller coaster this year.
Today we highlighted 4 'cheap' stocks that are currently trading for under $10 per share that also sport a Zacks Rank 2 (Buy) or better that investors might want to consider buying right now...